08:30:42 EDT Sun 22 Jul 2018
Enter Symbol
or Name
USA
CA



GeneNews Ltd (2)
Symbol C : GEN
Shares Issued 143,288,177
Close 2018-07-10 C$ 0.08
Recent Sedar Documents

GeneNews appoints Byram chief commercial officer

2018-07-12 09:33 ET - News Release

Mr. James Howard-Tripp reports

GENENEWS' INNOVATIVE DIAGNOSTIC LABORATORY APPOINTS DAVID BYRAM CHIEF COMMERCIAL OFFICER

GeneNews Ltd. has appointed David Byram as the chief commercial officer for its U.S. lab, Innovative Diagnostic Laboratory LLP (IDL). Mr. Byram will oversee all IDL's customer-facing activities including sales, client relations and commercial operations.

Mr. Byram is a senior commercial executive with over 25 years of pharmaceutical, biotechnology and medical device industry leadership experience. He has built successful product launches across multiple therapeutic areas that incorporate innovative sales and marketing strategies which have driven wide market adoption and revenue generation. Mr. Byram has broad health category experience including oncology/hematology, gastroenterology, rheumatology, neurology, cardiology and urology. During his career, Mr. Byram has overseen all commercial operations including sales and marketing, market access and pricing, channel strategy, and new product development. Prior to joining IDL, Mr. Byram was the vice-president, commercial and government affairs, for Braeburn Pharmaceuticals. Prior to Braeburn, he held positions as senior VP, commercial affairs, for Orexo AB/US, U.S. director, public sector, for Indivior PLC and senior director, strategic accounts and public affairs, for Janssen Biotech, a division of Johnson & Johnson. Mr. Byram is highly focused on delivering health care outcomes which create value for patients, physicians, payers and investors.

"We are extremely pleased to have David join IDL's senior leadership team," commented James R. Howard-Tripp, chairman and chief executive officer of GeneNews. "With a very experienced executive to energetically manage the company's commercial operations and sales strategy, we can increase the pace of meeting our targeted sales objectives for 2018."

"It is an exciting time to be in the liquid biopsy space and I look forward to utilizing my commercialization expertise as well as prior sales experience in oncology and gastroenterology to support IDL's efforts to achieve our growth objectives and ensure the highest satisfaction of our clients," said Mr. Byram.

About GeneNews Ltd.

GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.